U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2022
358
Substance Class Protein
Created
by admin
on Sat Dec 16 13:55:48 GMT 2023
Edited
by admin
on Sat Dec 16 13:55:48 GMT 2023
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG4
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
AF75XOF6W3
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
RELATLIMAB
USAN   INN  
Official Name English
IMMUNOGLOBULIN G4, ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE-3 PROTEIN) (HUMAN HEAVY CHAIN), DISULFIDE WITH HUMAN LIGHT CHAIN, DIMER
Systematic Name English
BMS-986016
Code English
BMS-986213 COMPONENT RELATLIMAB
Common Name English
relatlimab [INN]
Common Name English
Relatlimab [WHO-DD]
Common Name English
RELATLIMAB [USAN]
Common Name English
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE 3 PROTEIN (LAG-3, PROTEIN FDC, CD223 ANTIGEN))
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 641718
Created by admin on Sat Dec 16 13:55:48 GMT 2023 , Edited by admin on Sat Dec 16 13:55:48 GMT 2023
FDA ORPHAN DRUG 595017
Created by admin on Sat Dec 16 13:55:48 GMT 2023 , Edited by admin on Sat Dec 16 13:55:48 GMT 2023
NCI_THESAURUS C134305
Created by admin on Sat Dec 16 13:55:48 GMT 2023 , Edited by admin on Sat Dec 16 13:55:48 GMT 2023
Code System Code Type Description
DRUG BANK
DB14851
Created by admin on Sat Dec 16 13:55:48 GMT 2023 , Edited by admin on Sat Dec 16 13:55:48 GMT 2023
PRIMARY
NCI_THESAURUS
C111999
Created by admin on Sat Dec 16 13:55:48 GMT 2023 , Edited by admin on Sat Dec 16 13:55:48 GMT 2023
PRIMARY
CAS
1673516-98-7
Created by admin on Sat Dec 16 13:55:48 GMT 2023 , Edited by admin on Sat Dec 16 13:55:48 GMT 2023
PRIMARY
INN
10735
Created by admin on Sat Dec 16 13:55:48 GMT 2023 , Edited by admin on Sat Dec 16 13:55:48 GMT 2023
PRIMARY
RXCUI
2596773
Created by admin on Sat Dec 16 13:55:48 GMT 2023 , Edited by admin on Sat Dec 16 13:55:48 GMT 2023
PRIMARY
DAILYMED
AF75XOF6W3
Created by admin on Sat Dec 16 13:55:48 GMT 2023 , Edited by admin on Sat Dec 16 13:55:48 GMT 2023
PRIMARY
WIKIPEDIA
Relatlimab
Created by admin on Sat Dec 16 13:55:48 GMT 2023 , Edited by admin on Sat Dec 16 13:55:48 GMT 2023
PRIMARY
FDA UNII
AF75XOF6W3
Created by admin on Sat Dec 16 13:55:48 GMT 2023 , Edited by admin on Sat Dec 16 13:55:48 GMT 2023
PRIMARY
CAS
1683572-29-3
Created by admin on Sat Dec 16 13:55:48 GMT 2023 , Edited by admin on Sat Dec 16 13:55:48 GMT 2023
ALTERNATIVE
USAN
CD-174
Created by admin on Sat Dec 16 13:55:48 GMT 2023 , Edited by admin on Sat Dec 16 13:55:48 GMT 2023
PRIMARY
From To
1_22 1_95
1_147 1_203
1_261 1_321
1_367 1_425
2_22 2_95
2_147 2_203
2_261 2_321
2_367 2_425
1_134 3_214
1_226 2_226
1_229 2_229
2_134 4_214
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_297
N 2_297
Related Record Type Details
LYMPHOCYTE ACTIVATION GENE 3 PROTEIN
TARGET -> INHIBITOR
RELATLIMAB-RMBW
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
RELATLIMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER AVERAGE PHYSICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966